The Maine Immunization Program (MIP) will be hosting an educational lunch and learn on Friday, July 30, 2021 at 12:00 PM to provide guidance on the new vaccine products, MenQuadfi & VAXELIS.

MIP staff will be joined by:

• Manufacturers of both vaccine products
• Dr. Amy Belisle, Maine’s Chief Child Health Officer, and
  
• Dr. Lawrence Losey, Pediatrician with Mid Coast Pediatrics.

The education will cover immunogenicity, safety, dosing, administration, and storage & handling. We encourage you to join us for this informative presentation.

Date: Friday July 30, 2021 Time: 12:00 PM

Join Zoom Meeting: https://zoom.us/j/92370855904?pwd=WTQ3S0tyVElSSkNFR3BzNmNHSFpWZz09#success

Meeting ID: 923 7085 5904

Passcode: vaccine

For questions on any immunization-related issue, please call (207) 287-3746 or email ImmunizeME.DHHS@maine.gov. Thank you for all that you do to keep Maine children safe from vaccine-preventable diseases

The meningococcal quadrivalent conjugate vaccine (MenACWY) vaccine formulation, MenQuadfi™ (Sanofi), is approved for use in individuals 2 years of age and older. The vaccine is administered as a single 0.5 mL intramuscular dose. Starting at 2 years of age, MenQuadfi is interchangeable with the other MenACWY vaccines, Menveo® (GSK) and Menactra® (Sanofi).For individuals younger than 2 years of age, Menveo can be used starting at 2 months of age and Menactra can be used starting at 9 months of age. For more information on MenQuadfi, see the package insert here.

Also available for ordering is VAXELIS™ (Sanofi and Merck), the new hexavalent vaccine indicated for protection against diphtheria, tetanus, pertussis, polio, hepatitis B, and Haemophilus influenzae type B (Hib).This is the first vaccine available in the U.S. which has a hepatitis B and Hib component in addition to DTaP and polio components. The vaccine is approved for use as a three-dose series in children from 6 weeks through 4 years of age (prior to the 5th birthday). The three-dose series consists of a 0.5 mL intramuscular injection administered at 2, 4 and 6 months of age. For more information on VAXELIS, see the package insert here.

This is the first vaccine available in the U.S. which has a hepatitis B and Hib component in addition to DTaP and polio components. The vaccine is approved for use as a three-dose series in children from 6 weeks through 4 years of age (prior to the 5th birthday). The three-dose series consists of a 0.5 mL intramuscular injection administered at 2, 4 and 6 months of age. For more information on VAXELIS, see the package insert here.

The Maine Immunization Program brochure can be downloaded here.